Haemonetics (HAE) Net Income towards Common Stockholders (2009 - 2026)

Haemonetics' Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at -$20.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 134.7% year-over-year to -$20.1 million; the TTM figure through Mar 2026 stood at $97.4 million (down 41.94% YoY), while the FY2026 annual figure was $97.3 million, down 41.97% from the prior year.
• Net Income towards Common Stockholders was -$20.1 million for Q1 2026 at Haemonetics, down from $44.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $58.0 million in Q1 2025 to a low of -$20.1 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged $29.5 million across 5 years, with a median of $33.1 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders jumped 546.27% in 2022, then slumped 134.7% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $32.9 million in 2022, then retreated by 5.17% to $31.2 million in 2023, then gained by 20.02% to $37.5 million in 2024, then gained by 19.42% to $44.8 million in 2025, then slumped by 144.94% to -$20.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$20.1 million (Q1 2026), $44.8 million (Q4 2025), and $38.7 million (Q3 2025), per Business Quant data.